Searching for your content...
In-Language News
Contact Us
888-776-0942 from 8 AM - 10 PM ET
Cardax, Inc., announced today that it is refocusing its business strategy on its astaxanthin dietary supplement ZanthoSyn® for consumer health. The...
Cardax, Inc. (OTCQB:CDXI) announced today the filing of a Form 15 with the U.S. Securities and Exchange Commission (the "SEC") to voluntarily suspend ...
Cardax, Inc. (OTCQB:CDXI) reported its Q1 2021 results. Highlights: Financial Results. Operating loss decreased from $906,031 in Q1 2020 to $771,312...
Cardax, Inc. (OTCQB:CDXI) reported its 2020 results. Highlights: Financial Results. Net loss for 2020 decreased from $5,093,037 in 2019 to $5,055,507 ...
Cardax, Inc. (OTCQB:CDXI) reported its Q3 2020 results. Highlights: Financial Results. Operating loss decreased from $1,191,711 in Q3 2019 to...
Cardax, Inc. (OTCQB:CDXI) reported its Q2 2020 results. Highlights: Financial Results. Net operating loss from the same quarter last year decreased...
Cardax, Inc. (OTCQB:CDXI) reported its Q1 2020 results. Highlights: Financial Results. Net losses from the same quarter last year decreased 11.7%,...
Cardax, Inc. (OTCQB:CDXI) reported its 2019 results. Highlights: CHASE Clinical Trial. On September 23, 2019, the Company announced findings from the ...
Cardax, Inc. (OTCQB:CDXI) today released a white paper outlining the potential role of astaxanthin in the treatment of coronavirus disease and is...
Cardax, Inc. (OTCQB:CDXI) today announced it will effect a 200-for-1 reverse stock split of its issued and outstanding common stock. Pursuant to the...
Cardax, Inc. (OTCQB:CDXI) announced results for the third quarter of 2019. Highlights were as follows: CHASE Clinical Trial. On September 23, 2019,...
Cardax, Inc. (OTCQB: CDXI) today announced results from the pre-specified interim review of its ongoing CHASE (Cardiovascular Health Astaxanthin...
Cardax, Inc. (OTCQB:CDXI) today filed its Quarterly Report on Form 10-Q for the quarter ended June 30, 2019. Recent developments include: CHASE...
Cardax, Inc. (OTCQB:CDXI) announced today that it filed a registration statement on Form S-1 with the Securities and Exchange Commission relating to...
Cardax, Inc. (OTCQB:CDXI) announced results for the quarter ended March 31, 2019, in its Quarterly Report on Form 10-Q filed May 15, 2019 with the...
Cardax, Inc. (OTCQB:CDXI) announced results for the year ended December 31, 2018, in its Annual Report on Form 10-K filed today with the SEC....
Cardax, Inc. (OTCQB: CDXI), a life sciences company focused on inflammatory health, today announced that its CEO, David G. Watumull, will present at...
Cardax, Inc. (OTCQB: CDXI) and GNC (NYSE: GNC) announced today that they are expanding the sales and marketing program for ZanthoSyn®, Cardax's...
Cardax, Inc. (OTCQB: CDXI) announced that Paresh N. Soni, M.D., Ph.D., the former Senior Vice President and Head of Development for Amarin...
Cardax, Inc. (OTCQB: CDXI) announced its results for the third quarter of 2018. Revenues from sales of ZanthoSyn®, its premium astaxanthin dietary...
Cardax, Inc. (OTCQB: CDXI) has launched its Cardiovascular Health Astaxanthin Supplement Evaluation (CHASE) clinical trial targeting cardiovascular...
Cardax, Inc. (OTCQB: CDXI) today announced its results for the second quarter of 2018. Revenues from sales of ZanthoSyn®, its premium astaxanthin...
Cardax, Inc. (OTCQB: CDXI) announced today that it successfully closed its warrant exchange offer ("Exchange Offer") on Friday, July 27, 2018, at...
Cardax, Inc. (OTCQB: CDXI) announced today that it is extending to July 27, 2018, the period for its offer ("Exchange Offer") to allow holders of...
Cardax, Inc. (OTCQB: CDXI) announced today that the Securities and Exchange Commission has declared effective the Company's Registration Statement on ...
Join PR Newswire for Journalists to access all of the free services designated to make your job easier.
In need of subject matter experts for your story? Submit a free ProfNet request and find the sources you need.